Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)

PURPOSE: This study aimed to assess efficacy and safety of anlotinib as a first- or second-line treatment for advanced or metastatic hepatocellular carcinoma (aHCC) and to identify the predictive plasma cytokines on efficacy of anlotinib. METHODS: It was a phase II clinical study. Patients with aHCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yongkun, Zhou, Aiping, Zhang, Wen, Jiang, Zhichao, Chen, Bo, Zhao, Jianjun, Li, Zhiyu, Wang, Liming, Bi, Xinyu, Zhao, Hong, Liu, Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286948/
https://www.ncbi.nlm.nih.gov/pubmed/33826043
http://dx.doi.org/10.1007/s12072-021-10171-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286948/
https://www.ncbi.nlm.nih.gov/pubmed/33826043
http://dx.doi.org/10.1007/s12072-021-10171-0

Ejemplares similares